Research Proqram Leaders Committee (RPLC) - The RPLC meets on the first Thursday of each month to discuss issues relevant to research opportunities and needs within the VICC. The meeting is co-chaired by the Director and Associate Director for Basic Science Research Programs. Other members include all Research Program Leaders and Co-Leaders, the Deputy Director, the Associate Director of Clinical Science Research Programs, the Associate Director for Prevention, Control and Population-Based Research, the Associate Director for Shared Resources, the Associate Director for CCSG Administration, and the Director Emeritus. This is an important forum in which program leaders exchange information about inter- and intra-programmatic research initiatives and provide updates about ongoing high impact research in each of the programs. Planning for new or modified shared resources, recruitments, inter-programmatic collaborations and other activities to enhance the programs occurs during these meetings. Another important charge of the RPLC is to review new requests for membership in VICC and to make recommendations to the Director. Membership applications are submitted detailing the cancer-related activities of prospective members. The RPLC evaluates the application for compliance with VICC membership criteria, the committee then judges the applicant for suitability for assignment to the appropriate research program and a recommendation is made to the Director, who has ultimate authority in appointing members. The RPLC also conducts an annual review of the VICC membership and assesses cancer-relevant funding and publications, program participation and cancer collaborations for each member. The most recent evaluation occurred in the fall of 2008. The RPLC also plays an important role in review of CCSG Pilot Project applications. The RPLC selects reviewers for the applications and ranks the applications after all reviews have been returned. This ranking process is important as most years only 15-20% of submitted applications can be funded.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-17
Application #
8544993
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
17
Fiscal Year
2013
Total Cost
$244,173
Indirect Cost
$86,081
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Sierra, Johanna C; Asim, Mohammad; Verriere, Thomas G et al. (2018) Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 67:1247-1260

Showing the most recent 10 out of 2462 publications